Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 6/20 | 1.00 |
| ▸ | ACE | P12821 | 3/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | HPGD | P15428 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | ECE1 | P42892 | 1/20 | 1.00 |
| ▸ | BLM | P54132 | 1/20 | 1.00 |
| ▸ | NPEPPS | P55786 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | CPA3 | P15088 | 1/20 | 0.62 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| (R)-Thiorphan SCHEMBL7312756 | 1.00 | MME (1.00) | MMEACEALDH1A1HPGDMAPK1 | |
| (S)-Thiorphan SCHEMBL49662 | 1.00 | MME (1.00) | MMEACEALDH1A1HPGDMAPK1 | |
| Thiorphan SCHEMBL399227 | 0.92 | MME (0.84) | MMEACEALDH1A1HPGDMAPK1 | |
| SCHEMBL8861649 | 0.91 | MME (0.83) | MMEACEALDH1A1HPGDMAPK1 | |
| SCHEMBL10447979 | 0.90 | MME (0.81) | MMEACEALDH1A1HPGDMAPK1 | |
| Thiorphan SCHEMBL10038977 | 0.88 | MME (0.78) | MMEACEALDH1A1HPGDMAPK1 | |
| SCHEMBL4442570 | 0.88 | MME (0.78) | MMEACEALDH1A1HPGDMAPK1 | |
| SCHEMBL10038979 | 0.88 | MME (0.78) | MMEACEALDH1A1HPGDMAPK1 | |
| SCHEMBL8861684 | 0.87 | MME (0.77) | MMEACEALDH1A1HPGDMAPK1 | |
| SCHEMBL7103054 | 0.85 | MME (0.74) | MMEACEALDH1A1HPGDMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 293 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4739293-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF AUTOIMMUNE DISORDERS | AZURA OPHTHALMICS LTD (IL) | 2026-05-13 | — | — | EP | claimed |
| CN-119332016-A | SNP molecular marker combination for constructing old mango DNA fingerprint and application | 西南科技大学 | 2025-01-21 | — | — | CN | claimed |
| WO-2025012700-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF AUTOIMMUNE DISORDERS | Azura Ophthalmics Ltd. (IL) | 2025-01-16 | — | — | WO | claimed |
| WO-2024100454-A2 | COMPOSITION AND METHODS FOR IMPROVING SIGNS AND SYMPTOMS OF OCULAR DISORDERS | Azura Ophthalmics Ltd. (IL) | 2024-05-16 | — | — | WO | claimed |
| US-20230285282-A1 | OCULAR IMPLANT CONTAINING AN ACTIVE INGREDIENT | OCULAR THERAPEUTIX INC (US) | 2023-09-14 | — | — | US | claimed |
| EP-4236943-A1 | OCULAR IMPLANT CONTAINING AN ACTIVE AGENT | Ocular Therapeutix, Inc. (US) | 2023-09-06 | — | — | EP | claimed |
| US-20220307034-A1 | INHIBITING APE2 EXPRESSION IN A SUBJECT TREATED WITH A DRUG AGENT THAT CAUSES INCREASED APE2 EXPRESSION | THE CLEVELAND CLINIC FOUNDATION | 2022-09-29 | — | — | US | claimed |
| WO-2022093818-A1 | OCULAR IMPLANT CONTAINING AN ACTIVE AGENT | OCULAR THERAPEUTIX, INC. (US) | 2022-05-05 | — | — | WO | claimed |
| WO-2012112945-A1 | USE OF MATRIX METALLOPROTEINASE INHIBITORS TO TREAT TUBERCULOSIS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2012-08-23 | — | — | WO | claimed |
| US-5403824-A | Administering a opioid, opioid-degrading enzyme inhibitor or enkephalin secretagogues or mixtures thereof; side effect reduction | THE PROCTER & GAMBLE COMPANY (US) | 1995-04-04 | — | — | US | claimed |
| WO-1994021242-A1 | METHODS FOR THE TREATMENT OF OSTEOPOROSIS | THE PROCTER & GAMBLE COMPANY (US) | 1994-09-29 | — | — | WO | claimed |
| US-4513009-A | GLYCINE, ALANINE AND SERINE DERIVATIVES | SOCIETE CIVILE BIOPROJET (FR) | 1985-04-23 | — | — | US | claimed |
| JP-8176100-A | — | — | None | — | — | JP | disclosed |
| EP-4739293-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF AUTOIMMUNE DISORDERS | AZURA OPHTHALMICS LTD (IL) | 2026-05-13 | — | — | EP | disclosed |
| EP-4739291-A2 | ADMINISTRATION OF KERATOLYTICS TO OCULAR AND PERIOCULAR SURFACES | AZURA OPHTHALMICS LTD (IL) | 2026-05-13 | — | — | EP | disclosed |
| EP-4729935-A2 | AUTOMATED CLINICAL DIAGNOSTIC SYSTEM AND METHOD | F. Hoffmann-La Roche AG (CH) | 2026-04-22 | — | — | EP | disclosed |
| EP-0075896-A2 | Pharmaceutical amides, and preparation, formulations and use thereof | THE WELLCOME FOUNDATION LIMITED (GB) | 1983-04-06 | — | — | EP | disclosed |
| EP-0075334-A2 | Pharmaceutical compounds, and preparation, formulations and use thereof | THE WELLCOME FOUNDATION LIMITED (GB) | 1983-03-30 | — | — | EP | disclosed |
| EP-0066956-A1 | Enkephalinase enzyme inhibiting compounds | PFIZER INC. (US) | 1982-12-15 | — | — | EP | disclosed |
| US-4329495-A | USEFUL AS ANALGESICS OR ANTICONVULSANTS, CHIRAL 2-(2-BENZYL-3-MERCAPTOPROPIONYLAMINO)-THIOBUTYRIC ACIDS, OR ALKANOL DERIVATIVES | PFIZER INC. (US) | 1982-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230285282-A1 | OCULAR IMPLANT CONTAINING AN ACTIVE INGREDIENT | ERBB2, BTK, ERBB3 | MME 3793/4885ACE 3726/4885ALDH1A1 1122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.